Evidence map›Paper›PMID 35220640›Full record

Observational studyAmerican journal of reproductive immunology (New York, N.Y. : 1989)2022

Does mRNA SARS-CoV-2 vaccine in the follicular fluid impact follicle and oocyte performance in IVF treatments?

Rasha Odeh-Natour, Maanit Shapira, Daniela Estrada, Sarit Freimann, Yana Tal, Yuval Atzmon, Asaf Bilgory, Nardin Aslih, Yasmin Shibli Abu-Raya, Einat Shalom-Paz

Abstract readObservational Study
In one paragraph

Observational study in American journal of reproductive immunology (New York, N.Y. : 1989), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Female reproduction and abnormal uterine bleeding after COVID-19 vaccination.Clinical and experimental reproductive medicine · 2023
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rasha Odeh-NatourLaniado Hospital, Department of Obstetrics and Gynecology, Netanya, Israel.
Maanit ShapiraLaboratory Division, Hillel Yaffe Medical Center, Hadera, Israel.
Daniela EstradaIVF Unit, Department of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Hadera, Israel.ORCID 0000-0001-6496-0834
Sarit FreimannLaboratory Division, Hillel Yaffe Medical Center, Hadera, Israel.
Yana TalLaboratory Division, Hillel Yaffe Medical Center, Hadera, Israel.
Yuval AtzmonIVF Unit, Department of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Hadera, Israel.
Asaf BilgoryIVF Unit, Department of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Hadera, Israel.
Nardin AslihIVF Unit, Department of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Hadera, Israel.
Yasmin Shibli Abu-RayaIVF Unit, Department of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Hadera, Israel.
Einat Shalom-PazRuth and Bruce Rappaport School of Medicine, The Technion-Institute of Technology, Haifa, Israel.ORCID 0000-0002-7785-4202

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

problemThe COVID-19 pandemic has many clinical manifestations. Rapid vaccine development raised concerns and speculations about future fertility outcomes and vaccine safety. We evaluated the effect of Pfizer-BioNTech mRNA SARS-CoV-2 vaccine on IVF treatment, oocyte and embryo quality, and pregnancy outcomes. METHOD OF STUDY: This prospective, observational cohort study was conducted in a referral IVF Unit, 3/2021-5/2021. We aimed to recruit all women undergoing IVF/ICSI cycles from 3/1-4/30/2021, 2-8 weeks after the second vaccination, and to analyze 50-60 samples in the 2-month period. Patients were categorized according to serum antibody levels: positive for spike (S), positive for nucleotide (N), or negative for both. On the day of ovum pick-up, follicular fluid and blood samples were analyzed for anti-nucleotide (anti-N) antibodies, and anti-spike (anti-S) antibodies, hormonal profile, C-reactive protein (CRP) and other metabolic parameters.

resultsOf 59 women enrolled, 37 reported being vaccinated and 22 were not. We found 97% correlation between anti-S and anti-N in the blood and the follicular fluid. Follicular fluid was analyzed based on antibody categorization. All IVF treatment parameters in the follicular fluids and serum were comparable, except CRP was significantly elevated among patients with anti-N antibodies (2.29 [1.42-6.08] vs. 4.11 [1.62-5.75] vs. 1.44 [.36-8.33]; p < .001). Pregnancy outcomes were comparable (44% vs. 33% vs. 50%; p = .97).

conclusionmRNA SARS-CoV-2 vaccine did not appear to affect treatment outcomes or ovarian reserves in the subsequent IVF cycle.

Indexed as

COVID-19Follicular FluidCOVID-19 VaccinesFemaleFertilization in VitroHumansMaleOocytesPandemicsPregnancyProspective StudiesRNA, MessengerSARS-CoV-2COVID-19 VaccinesRNA, MessengerCovid-19C-reactive protein levelfollicular fluidmRNA SARS-CoV-2 vaccinepregnancy rate

Identifiers

PMID35220640
PMCPMC9111235

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.